IPC분류정보
| 국가/구분 |
United States(US) Patent
등록
|
| 국제특허분류(IPC7판) |
|
| 출원번호 |
US-0910387
(2001-07-20)
|
|
발명자
/ 주소 |
- Kunz, Lawrence L.
- Klein, Richard A.
|
| 출원인 / 주소 |
|
| 대리인 / 주소 |
Schwegman, Lundberg, Woessner & Kluth, P.A.
|
| 인용정보 |
피인용 횟수 :
58 인용 특허 :
137 |
초록
▼
Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a ce
Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.
대표청구항
▼
Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a ce
Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. ,NH(C1-3alkyl), N(C1-3alkyl)2,C(=NH)NH2,CH2NH2,CH2NH(C1-3alkyl), CH2N(C1-3alkyl)2,CH2CH2NH2,CH2CH2NH(C1-3alkyl), CH2CH2N(C1-3alkyl)2,(CR8R9)tNR7R8,(CR8R9)tC(O)NR7R8,and OCF3; M is isoxazoline, pyrazoline, isothiazoline, triazoline, tetrazoline, phenyl, or a 5-6 membered aromatic heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from O, N, and S, and is substituted with -Z-A-B; M is also substituted with 0-2 R1a; Z is selected from a bond, --(CR2R2a)1-4--, (CR2R2a)qO(CR2R2a)q1, (CR2R2a)qNR3(CR2R2a)q1, (CR2R2a)qC(O)(CR2R2a)q1, (CR2R2a)qC(O)O(CR2R2a)q1, (CR2R2a)qOC(O)(CR2R2a)q1, (CR2R2a)qC(O)NR3(CR2R2a)q1, (CR2R2a)qNR3C(O)(CR2R2a)q1, (CR2R2a)qOC(O)O(CR2R2a)q1, (CR2R2a)qOC(O)NR3(CR2R2a)q1, (CR2R2a)qNR3C(O)O(CR2R2a)q1, (CR2R2a)qNR3C(O)NR3(CR2R2a)q1, (CR2R2a)qS(CR2R2a)q1, (CR2R2a)qS(O)(CR2R2a)q1, (CR2R2a)qS(O)2(CR2R2a)q1, (CR2R2a)qSO2NR3(CR2R2a)q1, (CR2R2a)qNR3SO2(CR2R2a)q1, and (CR2R2a)qNR3SO2NR3(CR2R2a)q1, wherein q+q1total 0, 1, or 2, provided that Z does not form a N--N, N--O, N--S, NCH2N, NCH2O, or NCH2S bond with either group to which it is attached; R1ais selected from H, --(CH2)r--R1b,--CH=CH--R1b,NCH2R1c,OCH2R1c,SCH2R1c,NH(CH2)2(CH2)tR1b,O(CH2)2(CH2)tR1b,S(CH2)2(CH2)tR1b,S(O)p(CH2)rR1b,O(CH2)rR1d,NR3(CH2)rR1b,OC(O)NR3(CH2)rR1d,NR3C(O)NR3(CH2)rR1d,NR3C(O)O(CH2)rR1d,and NR3C(O)(CH2
※ AI-Helper는 부적절한 답변을 할 수 있습니다.